全文获取类型
收费全文 | 3897篇 |
免费 | 284篇 |
国内免费 | 21篇 |
专业分类
耳鼻咽喉 | 23篇 |
儿科学 | 123篇 |
妇产科学 | 73篇 |
基础医学 | 571篇 |
口腔科学 | 70篇 |
临床医学 | 452篇 |
内科学 | 791篇 |
皮肤病学 | 116篇 |
神经病学 | 331篇 |
特种医学 | 115篇 |
外科学 | 375篇 |
综合类 | 19篇 |
一般理论 | 1篇 |
预防医学 | 386篇 |
眼科学 | 106篇 |
药学 | 232篇 |
中国医学 | 11篇 |
肿瘤学 | 407篇 |
出版年
2024年 | 7篇 |
2023年 | 41篇 |
2022年 | 89篇 |
2021年 | 139篇 |
2020年 | 84篇 |
2019年 | 134篇 |
2018年 | 113篇 |
2017年 | 95篇 |
2016年 | 109篇 |
2015年 | 107篇 |
2014年 | 144篇 |
2013年 | 214篇 |
2012年 | 301篇 |
2011年 | 311篇 |
2010年 | 156篇 |
2009年 | 139篇 |
2008年 | 260篇 |
2007年 | 214篇 |
2006年 | 238篇 |
2005年 | 247篇 |
2004年 | 188篇 |
2003年 | 188篇 |
2002年 | 185篇 |
2001年 | 31篇 |
2000年 | 17篇 |
1999年 | 39篇 |
1998年 | 38篇 |
1997年 | 30篇 |
1996年 | 30篇 |
1995年 | 26篇 |
1994年 | 16篇 |
1993年 | 10篇 |
1992年 | 13篇 |
1991年 | 9篇 |
1990年 | 7篇 |
1989年 | 8篇 |
1988年 | 14篇 |
1987年 | 8篇 |
1986年 | 11篇 |
1985年 | 9篇 |
1984年 | 12篇 |
1983年 | 8篇 |
1982年 | 11篇 |
1981年 | 15篇 |
1980年 | 16篇 |
1979年 | 12篇 |
1978年 | 8篇 |
1977年 | 7篇 |
1973年 | 6篇 |
1971年 | 9篇 |
排序方式: 共有4202条查询结果,搜索用时 17 毫秒
81.
Zuliani G Galvani M Bonetti F Prandini S Magon S Gasperini B Ruggiero C Cherubini A 《Archives of gerontology and geriatrics》2012,54(1):214-217
Some studies suggest that previous treatment with antiplatelet agents (AA) might reduce ischemic stroke severity and improve outcomes in terms of clinical deficits or mortality. We evaluated the effect of the prior chronic use of AA on short-term (30 days) mortality in a sample of consecutive patients with AIS. Four hundred thirty-nine older patients (>65 years) with “major” AIS (modified Rankin scale ≥ 3) consecutively admitted to the University ward of Internal Medicine or Geriatrics were enrolled. Stroke was classified according to Oxfordshire Community Stroke Project (OCSP). Data recorded included: (1) clinical features; (2) medical history including home therapies, and vascular risk factors; (3) routine clinical chemistry analyzes (verb)/analyses (noun). Short-term (30 days) mortality was 27.6%. One hundred fifteen subjects (26.2%) were taking AA before admission. Compared with subjects not treated, subjects taking AA were characterized by higher prevalence of recurrent stroke (35% vs. 22%). In this group, a trend toward a higher prevalence of congestive heart failure (CHF), smoking, and altered levels of consciousness (ALC) was noted. Stroke type and short-term mortality (33% vs. 26.2%; odds ratio = OR = 1.25; 95% confidence interval = CI = 0.75-2.10, age and gender adjusted) were not different between the two groups. Adjustment for glucose, CHF, previous stroke, smoking, and ALC did not change mortality risk (OR = 0.83; 95%CI = 0.40-1.72). We conclude that in older patients hospitalized for “major” AIS, prior use of AA was not associated with any benefit in terms of short-term mortality both in patients with first, as well as in those with recurrent ischemic stroke. 相似文献
82.
Meune C Twerenbold R Drexler B Balmelli C Wolf C Haaf P Reichlin T Irfan A Reiter M Zellweger C Meissner J Stelzig C Freese M Capodarve I Mueller C 《The American journal of cardiology》2012,109(8):1117-1123
We hypothesized that midregional pro-A-type natriuretic peptide (MR-proANP), the stable midregional epitope of proANP, might be useful in the early diagnosis and risk stratification of patients with suspected acute myocardial infarction (AMI). In this multicenter study we measured MR-proANP, cardiac troponin T (cTnT), and high-sensitive cTnT (hs-cTnT) at presentation in 675 consecutive patients presenting to the emergency department with suspected AMI. The final diagnosis was adjudicated by 2 independent cardiologists. Patients were followed 360 days for mortality and AMI. AMI was the final diagnosis in 119 patients (18%). Median MR-proANP levels at presentation were significantly higher in patients with AMI (189 pmol/L, interquartile range 97 to 341) versus patients with another final diagnosis (83 pmol/L, 49 to 144, p <0.001). However, neither the combination of MR-proANP with cTnT nor its combination with hs-cTnT significantly improved diagnostic accuracy as quantified by area under the receiver operating characteristic curve (0.91 vs 0.89 for cTnT alone, p = 0.086; 0.95 vs 0.96 for hs-cTnT, respectively, p = 0.02). Cumulative 360-day mortality/AMI rates were 2.4% in the first, 3.6% in the second, 9.5% in the third, and 18.8% in the fourth quartiles of MR-proANP (p <0.001). MR-proANP (area under the curve 0.76) predicted mortality/AMI independently of and more accurately than cTnT (area under the curve 0.62), hs-cTnT (area under the curve 0.71), and Thrombolysis In Myocardial Infarction risk score (area under the curve 0.72). Net reclassification improvements offered by the additional use of MR-proANP were 0.388 (p <0.001), 0.425 (p <0.001), and 0.217 (p = 0.007), respectively. In conclusion, MR-proANP improves risk prediction for 360-day mortality/AMI but does not seem to help in the early diagnosis of AMI. 相似文献
83.
Passman RS Bennett CL Purpura JM Kapur R Johnson LN Raisch DW West DP Edwards BJ Belknap SM Liebling DB Fisher MJ Samaras AT Jones LG Tulas KM McKoy JM 《The American journal of medicine》2012,125(5):447-453
Although amiodarone is the most commonly prescribed anti-arrhythmic drug, its use is limited by serious toxicities, including optic neuropathy. Current reports of amiodarone-associated optic neuropathy identified from the Food and Drug Administration's Adverse Event Reporting System and published case reports were reviewed. A total of 296 reports were identified: 214 from the Adverse Event Reporting System, 59 from published case reports, and 23 from adverse events reports for patients enrolled in clinical trials. Mean duration of amiodarone therapy before vision loss was 9 months (range 1-84 months). Insidious onset of amiodarone-associated optic neuropathy (44%) was the most common presentation, and nearly one third were asymptomatic. Optic disk edema was present in 85% of cases. Following drug cessation, 58% had improved visual acuity, 21% were unchanged, and 21% had further decreased visual acuity. Legal blindness (<20/200) was noted in at least one eye in 20% of cases. Close ophthalmologic surveillance of patients during the tenure of amiodarone administration is warranted. 相似文献
84.
85.
86.
Airiau K Mahon FX Josselin M Jeanneteau M Turcq B Belloc F 《Experimental hematology》2012,40(5):367-78.e2
Chronic myeloid leukemia (CML) tumorigenicity is driven by the oncogenic BCR-ABL tyrosine kinase. Specific tyrosine kinase inhibitors (TKI) have been designed and are now used for the treatment of CML. These TKI induce apoptosis in leukemic cells in a BIM-dependent mechanism. We hypothesized that an increase in BIM activity could sensitize CML cells to TKI. We blocked the anti-apoptotic proteins of the Bcl-2 family by using ABT-737, a Bcl-2 and Bcl-XL inhibitor. ABT-737 modified Bcl-2 protein interactions toward a pro-apoptotic phenotype. Its combination with TKI resulted in a strong synergism in CML cell lines. The association also induced a large decrease in X-linked inhibitor of apoptosis (XIAP), followed by caspase-3 activation. This XIAP decrease was due to post-translational events. The mitochondrial serine protease HtrA2/Omi was identified as being responsible for this off-target effect. Then, ABT-737 and TKI cooperate at several levels to induce apoptosis of CML cells lines, and the benefit of this association was also observed in CML hematopoietic progenitors. Interestingly, a lethal effect was also observed in the more immature CD34(+)CD38(-) TKI-insensitive population. Combination therapy might by an interesting strategy for the treatment of CML patients. 相似文献
87.
88.
Martin Schimmel Beatrice Leemann Armin Schnider François R. Herrmann Stavros Kiliaridis Frauke Müller 《Clinical oral investigations》2013,17(3):867-876
Objectives
Recovery from stroke-related oro-facial impairment has rarely been investigated. In this longitudinal study chewing efficiency, maximum lip and bite force as well as masseter muscle thickness were evaluated and compared with hand-grip force.Materials and methods
Thirty-one hospitalized stroke patients and 24 controls were recruited for this cohort study with 2-year follow-up. Chewing efficiency was evaluated with a color mixing ability test, lip forces with a traction dynamometer, bite force with a digital gauge, masseter muscle thickness using ultrasound measurements and grip strength with a hand dynamometer.Results
During the 2-year observation period, patients were evaluated four times. A total of 21 patients dropped out of the study. Stroke patients showed significantly impaired chewing efficiency and lower lip forces than controls with no significant improvement over time. Bite forces were not different between ipsi- and contralesional sides, in contrast to contralesional hand-grip strength which was significantly impaired and did not improve during the observation period. On the first examination with a median of 40 days after stroke, masseter thickness was reduced contralesional, but did not continue to show significant side-differences during follow-up.Conclusions
Stroke affects the upper limb and the masseter muscles differently on a functional and morphological level. Further research is needed to evaluate the predictive value of oro-facial parameters on functional outcome after stroke.Clinical relevance
Impaired chewing efficiency and reduced lip force are quantifiable symptoms in stroke patients which seem not to improve in absence of oro-facial rehabilitation procedures. 相似文献89.
90.
Giuseppe Martini Andrea Mignarri Martina Ruvio Roberto Valenti Beatrice Franci Marina Del Puppo Antonio Federico Ranuccio Nuti Maria Teresa Dotti 《Calcified tissue international》2013,92(3):282-286
Cerebrotendinous xanthomatosis (CTX) is known to be associated with osteoporosis and a higher incidence of bone fractures. However, the underlying pathogenesis is still unknown, and the effects of long-term replacement therapy with chenodeoxycholic acid (CDCA) on bone mineral density (BMD) have not been fully investigated. We studied 11 CTX patients aged 13–43 years. We performed dual-energy X-ray absorptiometry and assessed serum cholestanol and 25-hydroxyvitamin D (25-OHD) concentrations both at the time of diagnosis and after long-term treatment with CDCA. At baseline, we found low BMD in nine patients, cholestanol elevation in all subjects, and 25-OHD decrease in nine. After a mean follow-up time of 30 months (range 24–36), no substantial clinical changes including bone fractures occurred; and we detected a significant increase of both planar and volumetric BMD as well as normalization of plasma cholestanol levels and increase of serum 25-OHD. Densitometric improvement following CDCA introduction was not correlated to changes of biochemical parameters. Our study confirms the presence of low bone mass in CTX and demonstrates that long-term CDCA treatment increases bone mineral content. In this respect, improvement of vitamin D intestinal absorption secondary to bile acid restoration could play an important role. Moreover, our data strongly suggest the utility of periodic bone density evaluation in CTX patients. 相似文献